tiprankstipranks
Advertisement
Advertisement

BHVN Stock Latest News

Biohaven announces completion of enrollment in RISE3 trial
The FlyBiohaven announces completion of enrollment in RISE3 trial
22h ago
BHVN
Biohaven falls -9.8%
PremiumThe Fly
Biohaven falls -9.8%
2d ago
BHVN
Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease
PremiumThe Fly
Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease
2d ago
BHVN
Biohaven downgraded to Underperform from Neutral at BofA
PremiumThe Fly
Biohaven downgraded to Underperform from Neutral at BofA
2d ago
BHVN
XENE
Biohaven rises 7.4%
PremiumThe Fly
Biohaven rises 7.4%
5d ago
BHVN
Biohaven price target raised to $20 from $15 at Deutsche Bank
PremiumThe FlyBiohaven price target raised to $20 from $15 at Deutsche Bank
5d ago
BHVN
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
27d ago
AZN
BMY
FDA issues draft guidance to help accelerated cell, gene therapies for patients
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
29d ago
AZN
BMY
Biohaven initiates first-in-human dosing for BHV-8100
PremiumThe Fly
Biohaven initiates first-in-human dosing for BHV-8100
30d ago
BHVN
Biohaven Showcases Promising Opakalim Epilepsy Data at R&D Day
PremiumCompany Announcements
Biohaven Showcases Promising Opakalim Epilepsy Data at R&D Day
1M ago
8K
BHVN
Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy
PremiumThe Fly
Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy
1M ago
BHVN
Douglas Tsao Maintains Hold on Biohaven, Keeps $10 Price Target Amid Promising but Early Epilepsy Data
PremiumRatings
Douglas Tsao Maintains Hold on Biohaven, Keeps $10 Price Target Amid Promising but Early Epilepsy Data
1M ago
BHVN
Biohaven reports data from selective Kv7.2/7.3 channel activator program
PremiumThe FlyBiohaven reports data from selective Kv7.2/7.3 channel activator program
1M ago
BHVN
Biohaven price target lowered to $18 from $21 at Morgan Stanley
Premium
The Fly
Biohaven price target lowered to $18 from $21 at Morgan Stanley
2M ago
BHVN
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
Premium
The Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
2M ago
AZN
BMY
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10
PremiumRatings
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10
2M ago
BHVN
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
2M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
2M ago
DYN
RNA
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures
PremiumCompany Announcements
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures
2M ago
BHVN
Biohaven Expands At-The-Market Equity Offering Program
PremiumCompany AnnouncementsBiohaven Expands At-The-Market Equity Offering Program
2M ago
8K
BHVN
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
Premium
Ratings
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
2M ago
BHVN
Biohaven price target lowered to $22 from $23 at RBC Capital
Premium
The Fly
Biohaven price target lowered to $22 from $23 at RBC Capital
2M ago
BHVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >